# Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

> **NCT07559864** · PHASE2 · RECRUITING · sponsor: **Jian Li** · enrollment: 100 (estimated)

## Conditions studied

- GIST - Gastrointestinal Stromal Tumor
- KIT Gene Mutation

## Interventions

- **DRUG:** physician-selected treatment
- **DRUG:** Regorafenib + Envafolimab

## Key facts

- **NCT ID:** NCT07559864
- **Lead sponsor:** Jian Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07559864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07559864, "Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07559864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*